Molecular Dx

Up-and-Coming Diagnostic Test Developers Emerge as Consolidation Thins the Field.

10 privately-held diagnostics developers primarily focused on liquid biopsy tests, ranked by total money raised from venture capital firms.

These ten governments have committed funding for projects that will sequence a minimum of 100,000 citizens to spur genomic medicine

If companion diagnostics (CDx) were people, they would be old enough to drink. The first CDx won FDA approval in 1998, when Dako Denmark...

The researchers looked to identify genetic differences with clinical outcomes. Using that study form, for each patient, the team identified an average of three disease-causing mutations involved in COVID-19 susceptibility.

Company expects to deliver 50,000 tests per day of the rapid, instrument-based, isothermal system designed for qualitative detection of infectious diseases.

It would be hard to find an area of health where the microbiome has not been implicated as a major player. The microbiome is...

The nation’s largest private health insurer, UnitedHealthcare, announced August 1 that it will cover testing that will allow physicians to match their patients to...

Researchers based at the Beaumont Health System in Michigan, have developed a test using a method known as Reverse Transcription Loop-Mediated Isothermal Amplification or RT-LAMP, that does not require the repeated heating cycles of PCR.

A growing number of diagnostics developers have set out to address the challenge of meeting the nation’s need for more COVID-19 tests. Here we profile five companies that have answered that challenge by working to bring new assays, with new technologies, to patients.